{
  "id": "6028fe391cb411341a000104",
  "type": "list",
  "question": "Which IDH inhibitors by Agios Pharmaceuticals have been approved by the FDA?",
  "ideal_answer": "Enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31660152"
  ],
  "snippets": [
    {
      "text": "Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration on 1 August 2017 and 20 July 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31660152",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Enasidenib, Ivosidenib"
}